Bleakley Financial Group LLC Sells 16,830 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Bleakley Financial Group LLC decreased its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 5.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 318,340 shares of the company’s stock after selling 16,830 shares during the quarter. Bleakley Financial Group LLC’s holdings in Takeda Pharmaceutical were worth $4,215,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in TAK. Versant Capital Management Inc bought a new stake in Takeda Pharmaceutical in the 4th quarter worth approximately $26,000. Wilmington Savings Fund Society FSB bought a new stake in Takeda Pharmaceutical in the 3rd quarter worth approximately $40,000. BNP Paribas Financial Markets increased its stake in Takeda Pharmaceutical by 416.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after acquiring an additional 2,596 shares during the last quarter. Smithfield Trust Co boosted its holdings in shares of Takeda Pharmaceutical by 76.9% in the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after purchasing an additional 1,490 shares during the period. Finally, Erste Asset Management GmbH purchased a new position in shares of Takeda Pharmaceutical in the 3rd quarter worth approximately $52,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock opened at $13.60 on Friday. The stock has a market cap of $43.26 billion, a price-to-earnings ratio of 33.99, a price-to-earnings-growth ratio of 0.23 and a beta of 0.51. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The stock has a 50 day moving average price of $13.30 and a 200-day moving average price of $13.88. Takeda Pharmaceutical Company Limited has a one year low of $12.57 and a one year high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Equities analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.